"As your company rushes to the finish line, be aware that the winner's trophy may no longer be an IPO. If you decide to bypass the sluggish public offering market, what are your
options? VCs and bankers are looking seriously at a number of alternatives to the traditional IPO exit strategy. What do you know about SPACs, shells and reverse mergers? Is London AIM an alternative? What are the advantages of each? What are the disadvantages? Who are your possible purchasers in an M&A scenario? Join us for a review of financing vehicles available to mezzanine-stage private companies, the pros and cons of each and a discussion of The Street's perception of alternative strategies for achieving liquidity."

Objective1:Analyze the current IPO market and provide insights into the wisest choice for a life science company.

Objective2:"Identify and describe various alternatives to the traditional
IPO exit."

Objective3:Educate on how to weigh the value of these alternatives in various situations.